Drugs / M1069
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05198349 | Mar 2022 → May 2023 | cancer of unknown primary site | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-28 | Domain Therapeutics SA | Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology domaintherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M1069 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05198349 ↗ |
| Route | Oral | “Participants received escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal...” NCT05198349 ↗ |